Advanced Biomed Inc
ADVB
$4.42 -3.28% Quote
Exchange NASDAQ Sector Healthcare Industry Medical Diagnostics Research
Q1 2026
Reported
Published: Nov 19, 2025

Data: Financial Modeling Prep

Company Status Snapshot

Fast view of the latest quarter outcome for ADVB

Report Date

Nov 19, 2025

Quarter Q1 2026

Revenue

N/A

YoY: N/A

EPS

-0.02

YoY: +57.1%

Market Move

-3.28%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Net Income

-386.90K

YoY: +58.5%

ADVB
Company ADVB

Swipe to view all report sections

Executive Summary

Advanced Biomed reported a negative net income of $-386,901 in QQ1 2026 (period ended 2025-09-30) driven by deliberate R&D and G&A investments while continuing to scale its microfluidic biochip platform and oncology detection portfolio. Operating expenses totaled $523,914, with depreciation of $47,992 and EBITDA of $-475,922, underscoring the company’s ongoing transition from a development-stage profile toward commercialization-readiness. The balance sheet shows a prudent liquidity position with cash and cash equivalents of $2.66 million and total debt of $1.70 million, yielding a net debt position of $-2.63 million and a reported cash position that supports near-term operational burn.

The company’s R&D expenditure of $235,992 represents a substantive investment into core platforms (APre, AC1000, CTC Enrichment, ACellScan) and related immunochromogenic kits (ACTCE, ACTCM, AEMT, ACM), with management signaling a strategic emphasis on advancing early cancer-detection capabilities (e.g., ALCGuard). However, absence of reported revenue for QQ1 2026 and the ongoing negative earnings trajectory imply that meaningful top-line progress remains a near-term hurdle. Management commentary was not captured in the provided transcript data, limiting the ability to quote call-specific guidance; nonetheless, the quarterly performance aligns with a growth-stage diagnostic company prioritizing product development, regulatory validation, and near-term partnerships over immediate profitability.

Key takeaway: ADVB possesses a solid liquidity runway and a compelling long-term oncology diagnostics pipeline, but the near-term investment thesis hinges on successful monetization through licensing, pilots, or regulatory-enabled deployments. Investors should monitor the cadence of pipeline milestones, potential licensing deals, and any revenue ramp signals in the upcoming quarters to confirm a trajectory toward sustainable profitability.

Key Performance Indicators

Operating Income
Increasing
-523.91K
QoQ: N/A | YoY: 30.85%
Net Income
Increasing
-386.90K
QoQ: 72.04% | YoY: 58.52%
EPS
Increasing
-0.02
QoQ: 71.01% | YoY: 57.08%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2026 0.00 -0.01 +0.0% View
Q2 2026 0.00 0.31 +0.0% View
Q1 2026 0.00 -0.02 +0.0% View
Q3 2024 0.00 -0.07 +0.0% View
Q2 2024 0.00 -0.05 +0.0% View